Effect of acute kidney injury and overall survival in patients with postoperative head and neck cancer who received chemoradiotherapy with cisplatin: A supplementary analysis of the phase II/III trial of JCOG1008.

ABSTRACT:

Background

In a randomized phase II/III trial (JCOG1008), weekly cisplatin (40 mg/m²) was non-inferior to 3-weekly cisplatin (100 mg/m²) for postoperative high-risk head and neck cancer. We investigated how acute kidney injury (AKI), a major dose-limiting toxicity effect of cisplatin, affects overall survival (OS).

Methods

We analyzed 251 patients from JCOG1008 receiving chemoradiotherapy. AKI was defined based on AKI Network criteria (serum creatinine increase of ≥0.3 mg/dL or ≥1.5-fold [≥ stage I]) within 30 days after completing chemoradiotherapy. OS in the two arms was compared according to AKI development using the log-rank test.

Results

The total incidence of AKI was lower in the weekly arm than in the 3-weekly arm (38/122 [31.1%] vs. 56/12

SUBMITTER: Imamura Y 

PROVIDER: S-EPMC11441389 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature